SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-227584
Filing Date
2021-07-29
Accepted
2021-07-28 17:38:32
Documents
16
Period of Report
2021-07-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d208399d8k.htm   iXBRL 8-K 40182
2 EX-10.1 d208399dex101.htm EX-10.1 46481
3 EX-10.2 d208399dex102.htm EX-10.2 55152
4 EX-99.1 d208399dex991.htm EX-99.1 16770
8 GRAPHIC g208399snap0002.jpg GRAPHIC 5232
  Complete submission text file 0001193125-21-227584.txt   335340

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA xers-20210728.xsd EX-101.SCH 2889
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE xers-20210728_lab.xml EX-101.LAB 18888
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xers-20210728_pre.xml EX-101.PRE 11858
9 EXTRACTED XBRL INSTANCE DOCUMENT d208399d8k_htm.xml XML 3481
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 211123926
SIC: 2834 Pharmaceutical Preparations